• Gavi's strategy

in page functions
  • Our 2016–2020 mission, to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower-income countries, is guided by four strategic goals

  • In June 2014, the Gavi Board approved a new five-year strategy to ensure we deliver on our overall mission for 2016–2020. Full implementation of the strategy will see developing countries immunise 300 million children, saving 5–6 million lives in the long term.

    Coverage and equity are at the core of our strategy. While we continue to support countries to introduce new vaccines, our focus is expanding to reach every child with these vaccines. With as many as 20 countries transitioning out of our financial support in this period, ensuring that programmes are sustainable in the long term is essential.

    Strategy - Phase IV Goals
  • The systems goal

    Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems.

  • Gavi's strategy is a roadmap designed to help us respond to changes in the vaccine landscape and set five-year milestones en route to fulfilling our mission. The 2016-2020 strategy is the latest in four distinct phases since our inception:

    This section details the strategic objectives and operating principles for the current phase (2016-2020) as well as providing an overview of previous strategies.

    You can also learn more about our vaccine investment strategy, which we use to determine which vaccines are made available to countries through our vaccine support programmes. A new strategy is developed every five years, when we take stock of available and expected vaccines and set new priorities through in-depth analysis and widespread consultations. The latest vaccine investment strategy was developed in 2013 and covers the period 2014-2018.

  • US$ 80-100 billion

    Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

    Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

    More facts...

close icon

modal window here